pulmonary surfactant


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

pulmonary surfactant

See surfactant, def. 2.

pulmonary surfactant

A lipoprotein secreted by type II alveolar cells that decreases the surface tension of the fluid lining the alveoli, permitting expansion. Synthetic lung surfactant is available for treating patients with respiratory distress syndrome. In obstetrics, fetal production of surfactant can be stimulated by administration of a glucocorticoid 24 to 48 hr before an inevitable preterm birth.
Synonym: lung surfactant See: betamethasone; lecithin-sphingomyelin ratio
See also: surfactant
References in periodicals archive ?
Immunohistochemistry in a significant portion of babies with the syndrome observed decrease in expression of surfactant protein B, probably due to qualitative changes in pulmonary surfactant.
On that point Brubaker was most impressed with Anthony Colucci's pulmonary surfactant studies, which, he wrote, came close to understanding the cause, or mechanism, of how smoking triggers emphysema.
The claims of the patent provide coverage for synthetic pulmonary surfactant compositions comprising of a combination of a proprietary synthetic peptide and various lipids.
As a quick reminder, respiratory distress syndrome (RDS) of the newborn is the seventh most common cause of perinatal mortality in the United States, and it is caused by a deficiency of pulmonary surfactant at birth.
ABCA3 as a lipid transporter in pulmonary surfactant biogenesis.
Current studies are investigating known polymorphisms in the pulmonary surfactant proteins important to host defense and in the Th2 cytokines, such as IL-13, that drive the asthma response.
Also referred to as hyaline membrane disease, respiratory distress syndrome results from an insufficient amount of pulmonary surfactant that is produced by the neonatal lung and released into the amniotic fluid.
A common feature of respiratory distress is a change in pulmonary surfactant, which is the surface lining of the lungs and is comprised of a complex mixture of phospholipids, neutral lipids and proteins.
Currently, treatment schemes for improving ventilation of newborns with respiratory failure include high-frequency oscillatory ventilation, the supplement of pulmonary surfactant, nitric oxide (NO) inhalation, liquid ventilation and extracorporeal membrane oxygenation.
10) demonstrated that both LDL and HDL cholesterol stimulate primary cultures of type II cells to secrete phosphatidylcholine, the major phospholipid component of pulmonary surfactant.
It is during this stage that type II pneumocytes increase production of pulmonary surfactant Lung development continues for approximately eight years.